These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25981165)

  • 1. Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.
    Li L; Vashisht K; Boisclair J; Li W; Lin TH; Schmid HA; Kluwe W; Schoenfeld H; Hoffmann P
    Toxicol Appl Pharmacol; 2015 Aug; 286(3):224-33. PubMed ID: 25981165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
    Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
    Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osilodrostat: First Approval.
    Duggan S
    Drugs; 2020 Apr; 80(5):495-500. PubMed ID: 32141023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicology and carcinogenesis studies of kava kava extract (CAS No. 9000-38-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2012 Mar; (571):1-186. PubMed ID: 22441424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
    Golor G; Hu K; Ruffin M; Buchelt A; Bouillaud E; Wang Y; Maldonado M
    Drug Des Devel Ther; 2012; 6():71-9. PubMed ID: 22573933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 May; (529):4-168. PubMed ID: 16835634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
    Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
    Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
    Petersenn S; Hu K; Maldonado M; Zhang Y; Lasher J; Bouillaud E; Wang Y; Mann K; Unger N
    Clin Ther; 2012 Mar; 34(3):677-88. PubMed ID: 22364824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
    Paton DP
    Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
    Petersenn S; Unger N; Hu K; Weisshaar B; Zhang Y; Bouillaud E; Reséndiz KH; Wang Y; Mann K
    J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450.
    Valentín-Goyco J; Liu J; Peng HM; Oommen J; Auchus RJ
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106316. PubMed ID: 37098354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2010 Nov; (558):1-206. PubMed ID: 21383777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.